Roche’s Hans Clevers sees organoid biobank as source of patient avatars 

Organoid pioneer Hans Clevers says regulatory agencies are eager for companies to submit organoid data, and Roche’s Institute of Human Biology aims to validate their use in predicting drug safety and efficacy.

Clevers is head of Pharma Research and Early Development (pRED) at Roche (SIX:ROG; OTCQX:RHHBY), which launched the Institute of Human Biology (IHB) in May to use human model systems such as organoids in exploratory research, bioengineering, and translation and technologies...